Population-based rates of treatment for prostate cancer: 2007-2012

The population-based rate of Medicare patients getting treatment for prostate cancer dropped by 42 percent from 2007 to 2012 … but this drop did not occur in patients who had a high risk of dying from a cause other than prostate cancer within 10 years, who are arguably among those who least need immediate treatment for prostate cancer (and especially for low-risk forms of prostate cancer). … READ MORE …

Incidence, outcomes, ethnicity, and distant, de novo, metastatic prostate cancer

Diagnosis of men with distant, metastatic prostate cancer at first presentation (distant, “de novo”, metastatic prostate cancer) is a lot less common today than it was 30 or 40 years ago, but it does still happen on a regular basis. … READ MORE …

SpaceOAR hydrogel — is the difference worthwhile?

SpaceOAR hydrogel is spacer injected between the rectum and the prostate that increases their separation (in men being treated with external beam radiation therapy). This allows less radiation targeted at the prostate to hit the rectum. The research group published an interim 15-month report in 2015, and now Hamstra et al. have published their final report based on 3 years of follow-up. … READ MORE …

All the lutetium-177 news that’s fit to discuss (when it first comes out)

There has been a lot of noise in the past week about the effectiveness of lutetium-177 linked to PSMA in the treatment of late stage prostate cancer. If you were looking for us to say something about this, Allen Edel already has, back in October last year, when the relevant article was first published on line and Allen promptly commented (click here to get his take).

Salvage HIFU as a treatment for radiorecurrent localized prostate cancer

Although there has been some exploratory work in this area, the available data on the outcomes of patients treated with high-intensity focused ultrasound (HIFU) as a form of salvage therapy for men with biochemical recurrence after first-line radiation therapy are extremely limited. … READ MORE …

“The PSA clock” by Dr. Michael Glodé

Dr. Michael Glodé is a medical oncologist who practices in Colorado, and who has extensive experience in the management of prostate cancer. He also blogs on a regular basis at prost8blog. Your sitemaster tries to remember to check in on that blog site from time to time because it has long been very clear that Dr. Glodé takes the needs of his patients very seriously. … READ MORE …

ADT + EDT in the treatment of advanced prostate cancer?

An article published on line last year in Anticancer Research has just come to our attention. It puts forward the relatively simple proposal that by combining androgen deprivation therapy (ADT) with estrogen deprivation therapy (EDT) we might be able to significantly impact the risk for development of castration-resistant prostate cancer (CRPC). … READ MORE …